Medication Persistence of Disease‐Modifying Antirheumatic Drugs and Anti–Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil

By  

ARTHRITIS CARE AND RESEARCH, Vol. 68, Iss. 10, 2016-10 ,pp. : 1489-1496

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease‐Modifying Therapy

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 5, 2015-05 ,pp. : 731-736

John Wiley & Sons Inc

Access to resources Recommend Favorite

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

By Kielhorn Adrian   Porter Duncan   Diamantopoulos Alexander   Lewis Gavin  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2639-2650

Informa Healthcare

Access to resources Recommend Favorite

The role of methotrexate and low‐dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naïve to disease‐modifying antirheumatic drugs

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 19, Iss. 7, 2016-07 ,pp. : 665-671

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 21, Iss. 2, 2018-02 ,pp. : 402-414

John Wiley & Sons Inc

Access to resources Recommend Favorite